Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

By afschroeder • August 12, 2025

Sitbon O, Sahay S, Escribano Subías P, Zolty RL, Kingrey JF, Ryan JJ, Sobol I, Sood N, Benza RL, Channick RN, Chin KM, Frantz RP, Ghofrani HA, Hemnes AR, McLaughlin VV, Vachiéry JL, Zamanian RT, Ter Veer A, Roscigno RF, Mottola D, Parsley E, Aranda R, Zisman LS, Howard LS; TORREY Study Investigators. Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study. Adv Ther. 2025 Aug 11. doi: 10.1007/s12325-025-03297-2. Epub ahead of print. PMID: 40788460.

Tags: efficacy, Inhaled tyrosine kinase inhibitor, long-term, PDGFR inhibitor, Publications, pulmonary arterial hypertension, pulmonary vascular resistance, Pulmonary, Critical Care & Sleep Medicine, safety, Seralutinib

Medical Societies in the United States: History, Purpose, Challenge, and Future Directions

Schiller G, Leer LR. Medical Societies in the United States: History, Purpose, Challenge, and Future Directions. Cureus. 2026 Jul 10;18(7):e112407. doi: 10.7759/cureus.112407. PMID: 42572655; PMCID:[...]

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, Bardia A, Sedrak MS. Patient-reported outcomes in clinical trials leading to breast cancer[...]

Advancing the Science and Application of Learning Health Systems in General Medical and Primary Care Practice

Washington DL, Bolen S, Sussman JB. Advancing the Science and Application of Learning Health Systems in General Medical and Primary Care Practice. J Gen Intern[...]